Why EXACT Sciences Corporation Could Underperform

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of EXACT Sciences Corporation slumped more than 4% today after Wedbush downgraded the biotechnology company from outperform to neutral.

So what: Along with the downgrade, analyst Zarak Khurshid planted a price target of $14, representing about 1% worth of downside to yesterday's close. So while momentum traders might be attracted to EXACT's price strength in recent weeks, Khurshid's call could reflect a sense on Wall Street that its valuation is becoming a bit stretched.

Now what: According to Wedbush, EXACT's risk/reward trade-off isn't too appealing at this point. "We anticipate FDA approval later in 2Q14 followed by a preliminary CMS coverage decision (i.e., reimbursement and testing interval) a few days later," said Khurshid. "Historically, expectations have been relatively high going into important EXAS events and more often than not, shares sell off on key news." When you couple EXACT's speculative nature with its still-hot stock price -- up more than 40% from its 52-week lows -- it's tough to disagree with Wedbush's cautious stance. 

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

The article Why EXACT Sciences Corporation Could Underperform originally appeared on Fool.com.

Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story